Somatization in Parkinson's Disease: A systematic review

Danilo Carrozzino; Per Bech; Chiara Patierno; Marco Onofrj; Bo Mohr Morberg; Astrid Thomas; Laura Bonanni; Mario Fulcheri

doi:10.1016/j.pnpbp.2017.05.011

Somatization in Parkinson's Disease: A systematic review

Danilo Carrozzino, Per Bech, Chiara Patierno, Marco Onofrj, Bo Mohr Morberg, Astrid Thomas, Laura Bonanni, Mario Fulcheri

Psychiatric Research Unit, Psychiatric Centre North Zealand, University Hospital of Copenhagen, Hillerød, Denmark

21 Citations (Scopus)

Abstract

The current systematic review study is aimed at critically analyzing from a clinimetric viewpoint the clinical consequence of somatization in Parkinson's Disease (PD). By focusing on the International Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive electronic literature research strategy on ISI Web-of-Science, PsychINFO, PubMed, EBSCO, ScienceDirect, MEDLINE, Scopus, and Google Scholar databases. Out of 2.926 initial records, only a total of 9 studies were identified as clearly relevant and analyzed in this systematic review. The prevalence of somatization in PD has been found to range between 7.0% and 66.7%, with somatoform disorders acting as clinical factor significantly contributing to predict a progressive cognitive impairment. We highlighted that somatization is a highly prevalent comorbidity affecting PD. However, the clinical consequence of such psychiatric symptom should be further evaluated by replacing the clinically inadequate diagnostic label of psychogenic parkinsonism with the psychosomatic concept of persistent somatization as conceived by the Diagnostic Criteria for Psychosomatic Research (DCPR).

Original language	English
Journal	Progress in neuro-psychopharmacology & biological psychiatry
Volume	78
Pages (from-to)	18-26
Number of pages	9
ISSN	0278-5846
DOIs	https://doi.org/10.1016/j.pnpbp.2017.05.011
Publication status	Published - 15 May 2017

Keywords

Journal Article
Review

Access to Document

10.1016/j.pnpbp.2017.05.011

Cite this

@article{1b474aeaa60f4c8fabbfdd35895977e3,

title = "Somatization in Parkinson's Disease: A systematic review",

abstract = "The current systematic review study is aimed at critically analyzing from a clinimetric viewpoint the clinical consequence of somatization in Parkinson's Disease (PD). By focusing on the International Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive electronic literature research strategy on ISI Web-of-Science, PsychINFO, PubMed, EBSCO, ScienceDirect, MEDLINE, Scopus, and Google Scholar databases. Out of 2.926 initial records, only a total of 9 studies were identified as clearly relevant and analyzed in this systematic review. The prevalence of somatization in PD has been found to range between 7.0% and 66.7%, with somatoform disorders acting as clinical factor significantly contributing to predict a progressive cognitive impairment. We highlighted that somatization is a highly prevalent comorbidity affecting PD. However, the clinical consequence of such psychiatric symptom should be further evaluated by replacing the clinically inadequate diagnostic label of psychogenic parkinsonism with the psychosomatic concept of persistent somatization as conceived by the Diagnostic Criteria for Psychosomatic Research (DCPR).",

keywords = "Journal Article, Review",

author = "Danilo Carrozzino and Per Bech and Chiara Patierno and Marco Onofrj and Morberg, {Bo Mohr} and Astrid Thomas and Laura Bonanni and Mario Fulcheri",

year = "2017",

month = may,

day = "15",

doi = "10.1016/j.pnpbp.2017.05.011",

language = "English",

volume = "78",

pages = "18--26",

journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier Inc",

}

TY - JOUR

T1 - Somatization in Parkinson's Disease

T2 - A systematic review

AU - Carrozzino, Danilo

AU - Bech, Per

AU - Patierno, Chiara

AU - Onofrj, Marco

AU - Morberg, Bo Mohr

AU - Thomas, Astrid

AU - Bonanni, Laura

AU - Fulcheri, Mario

PY - 2017/5/15

Y1 - 2017/5/15

N2 - The current systematic review study is aimed at critically analyzing from a clinimetric viewpoint the clinical consequence of somatization in Parkinson's Disease (PD). By focusing on the International Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive electronic literature research strategy on ISI Web-of-Science, PsychINFO, PubMed, EBSCO, ScienceDirect, MEDLINE, Scopus, and Google Scholar databases. Out of 2.926 initial records, only a total of 9 studies were identified as clearly relevant and analyzed in this systematic review. The prevalence of somatization in PD has been found to range between 7.0% and 66.7%, with somatoform disorders acting as clinical factor significantly contributing to predict a progressive cognitive impairment. We highlighted that somatization is a highly prevalent comorbidity affecting PD. However, the clinical consequence of such psychiatric symptom should be further evaluated by replacing the clinically inadequate diagnostic label of psychogenic parkinsonism with the psychosomatic concept of persistent somatization as conceived by the Diagnostic Criteria for Psychosomatic Research (DCPR).

AB - The current systematic review study is aimed at critically analyzing from a clinimetric viewpoint the clinical consequence of somatization in Parkinson's Disease (PD). By focusing on the International Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive electronic literature research strategy on ISI Web-of-Science, PsychINFO, PubMed, EBSCO, ScienceDirect, MEDLINE, Scopus, and Google Scholar databases. Out of 2.926 initial records, only a total of 9 studies were identified as clearly relevant and analyzed in this systematic review. The prevalence of somatization in PD has been found to range between 7.0% and 66.7%, with somatoform disorders acting as clinical factor significantly contributing to predict a progressive cognitive impairment. We highlighted that somatization is a highly prevalent comorbidity affecting PD. However, the clinical consequence of such psychiatric symptom should be further evaluated by replacing the clinically inadequate diagnostic label of psychogenic parkinsonism with the psychosomatic concept of persistent somatization as conceived by the Diagnostic Criteria for Psychosomatic Research (DCPR).

KW - Journal Article

KW - Review

U2 - 10.1016/j.pnpbp.2017.05.011

DO - 10.1016/j.pnpbp.2017.05.011

M3 - Review

C2 - 28522290

VL - 78

SP - 18

EP - 26

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

ER -

Somatization in Parkinson's Disease: A systematic review

Abstract

Keywords

Access to Document

Fingerprint

Cite this